MACSF

COMMUNIQUÉS West-GlobeNewswire

Telix Precision Medicine Announces AlFluor Radiochemistry Platform
20/06/2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET 1 radiochemistry [...]
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
20/06/2025
SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple [...]
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
20/06/2025
– R esearch supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate [...]
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
20/06/2025
LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK ® (ripretinib), [...]
GoPath Diagnostics Announces Launch of DiabetesNow: A Genetic Test Panel Designed to Clarify Diabetes Diagnosis
20/06/2025
GoPath Diagnostics, a leading provider of molecular and digital pathology services, today announced the launch of DiabetesNow, a comprehensive genetic test developed to support the diagnosis, classification, and [...]
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
20/06/2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the [...]
IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant
20/06/2025
Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients 1 , 2 Positive opinion reinforces Phase 3 TRIANGLE study results by the European MCL Network, showing [...]
DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma
20/06/2025
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease interception 1 [...]
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
20/06/2025
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trial European Commission decision expected in August 2025 ; if approved, resmetirom will [...]
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
20/06/2025
ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of [...]
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
20/06/2025
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue- [...]
Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées
20/06/2025
S’il est approuvé, Cabometyx® sera le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines précédemment traitées, indépendamment de la localisation de la tumeur, de [...]
Dr. Anosh Ahmed’s Philanthropic Vision: Empowering Underserved Chicago Communities
20/06/2025
Chicago physician and entrepreneur Dr. Anosh Ahmed expands long-term community initiatives focused on healthcare, education, and economic relief through the Anosh Ahmed Foundation. Dr. Anosh Ahmed Image CHICAGO, June 20 [...]
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
20/06/2025
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotech company developing exosome-based therapies for [...]
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
20/06/2025
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing [...]
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
20/06/2025
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral [...]
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
20/06/2025
Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission [...]
Carbios presents the results of its Annual General Meeting of 19 June 2025 and the composition of its Board of Directors
20/06/2025
Clermont-Ferrand (France), June 20, 2025 (6:45 am CEST). CARBIOS , (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and [...]
CARBIOS présente les résultats de son Assemblée Générale du 19 juin 2025 et la composition de son Conseil d’administration
20/06/2025
Clermont-Ferrand (France), le 20 juin 2025 (06h45 CEST). CARBIOS, (Euronext Growth Paris : ALCRB), pionnière dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de vie des [...]

Pages